Take the gains today from ONVO and buy VRNG. VRNG has many more catalysts in the near term. Once you build back your ONVO losses with VRNG then reinvest in ONVO when it's around a buck 4-5 months from now.
Understood Bomba and maybe I appear to cynical but I know from experience that these type of deals are longshots as nothing has been accomplished other than a contract for a development project with some bells and whistles. Immediate revenue from this is less than $200K over the next 2 years in my opinion. More important is the lack of data the company produced at society of toxicology in San Diego 2 weeks ago. The exhibitor hosted session was a disaster as they didn't meet any expectations of data presentation but instead leaded a round-table discussion on the needs for advanced liver models. Basically this screamed that they have nothing ready for prime -time and just a BS marketing exercise. Oh and speaking of marketing you should see the new advertisements they produced for SOT. The most morbid, awful piece of marketing I've ever seen in my 25 years in the life Science industry.
Please!... this deal is based on feasibility of an undeveloped model for L'Oreal's needs. Potentially great news but this is a very long-term development project which needs to pass many hurdles before any serious revenue is captured. 2-3 5 years! This retail horde of investors in ONVO is absolutely nuts in my opinion. cool it and take a back seat until they develop models which are non-exclusive and have some real commercial prowess.
Are you insane? just because the collaborate loosely and I mean loosely you shouldn't draw assumptions that this was screened on the ONVO platform? before testing biologics on the platform one would start with small molecules... walk before you run ...know what I mean. If they are showing clinical data that means this program is years old having tested it in rodent, dog, Cyno in vivo before sticking it in humans. This was done years ago. Bad pumpers!
I'm very familiar with the advanced 3D liver models in the marketplace and please know that both Hepregen and InSphero models recapitulate the in vivo liver toxicity not currently seen in 2D assays. Both of the technologies have numerous studies and publications. Next week actually kicks off the Society of Toxicology meeting in San Diego where these two companies will present more data with global collaborations. The cost of these models are a substantial selling point if you consider the screening needs for pharmaceutical safety groups. As a toxicologist I see little evidence from the Onvo model and what has been published to date, that their cost justifies the models ability to better predict... in a screening capacity... human toxicity.